Respiratory Delivery of Gemcitabine for the Treatment of Lung Cancer

QUENCH MEDICAL, LONZA
6/14/22, 10:30 AM
America/Pacific Time UTC -8:00 / -7:00

Description

Event Overview:

 

Respiratory drug delivery relies heavily on particle engineering to control delivery of pharmaceuticals to target tissues. Process selection becomes even more crucial when supporting novel formulation approaches to drug delivery to the lungs. The speakers Bryce Beverlin II (Quench Medical) and Maureen Kadleck (Lonza Small Molecules) will use the case study of an Excipient Enhanced Growth for gemcitabine as an inhaled lung cancer treatment to illustrate a pathway from feasibility studies through scale-up to commercialization. There will be an emphasis on process design choices using traditional particle engineering approaches, and the new process capabilities needed to achieve the desired target product profile.

 

Key Learning Objectives:

  • Gain an understanding of the excipient enhanced growth platform
  • Find out more about spray drying scale-up and lifecycle
Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

Respiratory Delivery of Gemcitabine for the Treatment of Lung Cancer

Inglês

 

Speakers

Maureen Kadleck, Bryce Beverlin II

 

Link to the Event

Banner to the Event

Respiratory Delivery of Gemcitabine for the Treatment of Lung Cancer